LONDON (Reuters) - Early estimates of the production a million doses of the University of Oxford’s experimental COVID-19 vaccine by September could be an underestimate depending on how quickly late-stage trials can be completed, a researcher said on Monday.
“There might be a million doses manufactured by September: that now seems like a remarkable underestimate, given the scale of what’s going on,” Adrian Hill of University of Oxford said, referring to the manufacturing capability of partner AstraZeneca.
“Certainly there’ll be a million doses around in September. What’s less predictable than the manufacturing scale-up is the incidence of disease, so when there’ll be an endpoint.”
He added it was possible that there would be vaccines available by the end of the year.
Reporting by Alistair Smout; Editing by Andrew Heavens
Our Standards: The Thomson Reuters Trust Principles.